Tag: Rxilient
Rxilient Biotech and Junshi Biosciences form Joint Venture to develop and commercialize Toripalimab in Southeast Asia
On 28th March 2023, Rxilient Biotech (a portfolio company of Legend Capital) and Junshi Biosciences made a joint announcement that two parties will form a joint venture to develop and commercialize toripalimab in Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, and Vietnam[1]. From left to right: CEO of Junshi Biosciences, Dr. Li Ning; Managing Director of Legend Capital, Executive Director of Rxilient, Mr. Hong Tan; Chairman, Chief Executive and President of CMS, Mr. Lam Kong; Chairman of Junshi Biosciences, Mr. Xiong Jun; CEO of Rxilient, Dr. Lee Ker Yin Toripalimab is an anti-PD-1 monoclonal antibody independently developed by ... Read more